Nabriva Therapeutics AG (NASDAQ:NBRV) major shareholder Hbm Healthcare Investments (Ca sold 44,231 shares of the business’s stock in a transaction dated Thursday, July 20th. The stock was sold at an average price of $10.50, for a total value of $464,425.50. Following the transaction, the insider now owns 2,421,367 shares of the company’s stock, valued at $25,424,353.50. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Large shareholders that own 10% or more of a company’s stock are required to disclose their transactions with the SEC.

Hbm Healthcare Investments (Ca also recently made the following trade(s):

  • On Monday, August 7th, Hbm Healthcare Investments (Ca sold 17,790 shares of Nabriva Therapeutics AG stock. The stock was sold at an average price of $10.50, for a total value of $186,795.00.
  • On Tuesday, August 8th, Hbm Healthcare Investments (Ca sold 19,803 shares of Nabriva Therapeutics AG stock. The stock was sold at an average price of $10.50, for a total value of $207,931.50.
  • On Friday, July 28th, Hbm Healthcare Investments (Ca sold 6,585 shares of Nabriva Therapeutics AG stock. The stock was sold at an average price of $10.51, for a total value of $69,208.35.
  • On Monday, July 24th, Hbm Healthcare Investments (Ca sold 160 shares of Nabriva Therapeutics AG stock. The stock was sold at an average price of $10.50, for a total value of $1,680.00.
  • On Tuesday, July 18th, Hbm Healthcare Investments (Ca sold 69,854 shares of Nabriva Therapeutics AG stock. The stock was sold at an average price of $10.51, for a total value of $734,165.54.
  • On Thursday, July 13th, Hbm Healthcare Investments (Ca sold 57,175 shares of Nabriva Therapeutics AG stock. The shares were sold at an average price of $10.53, for a total value of $602,052.75.
  • On Friday, July 7th, Hbm Healthcare Investments (Ca sold 2,695 shares of Nabriva Therapeutics AG stock. The shares were sold at an average price of $10.52, for a total value of $28,351.40.
  • On Friday, June 30th, Hbm Healthcare Investments (Ca sold 1,775 shares of Nabriva Therapeutics AG stock. The shares were sold at an average price of $10.94, for a total value of $19,418.50.
  • On Monday, July 3rd, Hbm Healthcare Investments (Ca sold 13,127 shares of Nabriva Therapeutics AG stock. The shares were sold at an average price of $10.94, for a total value of $143,609.38.
  • On Thursday, June 29th, Hbm Healthcare Investments (Ca sold 8,558 shares of Nabriva Therapeutics AG stock. The shares were sold at an average price of $10.96, for a total value of $93,795.68.

Shares of Nabriva Therapeutics AG (NASDAQ NBRV) traded down 0.23% on Friday, hitting $8.81. The stock had a trading volume of 3,730 shares. The company’s market cap is $236.44 million. The company has a 50-day moving average of $10.19 and a 200-day moving average of $10.38. Nabriva Therapeutics AG has a 52-week low of $3.52 and a 52-week high of $12.75.

Nabriva Therapeutics AG (NASDAQ:NBRV) last issued its quarterly earnings data on Monday, August 7th. The biotechnology company reported ($0.54) EPS for the quarter, topping analysts’ consensus estimates of ($5.83) by $5.29. The business had revenue of $1.05 million during the quarter, compared to the consensus estimate of $1.34 million. On average, equities analysts anticipate that Nabriva Therapeutics AG will post ($2.40) EPS for the current fiscal year.

TRADEMARK VIOLATION NOTICE: “Insider Selling: Nabriva Therapeutics AG (NBRV) Major Shareholder Sells 44,231 Shares of Stock” was posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this story on another site, it was copied illegally and republished in violation of US and international trademark & copyright law. The correct version of this story can be read at https://www.thecerbatgem.com/2017/08/19/nabriva-therapeutics-ag-nbrv-major-shareholder-sells-464425-50-in-stock-updated-updated-updated.html.

Institutional investors have recently added to or reduced their stakes in the company. Nationwide Fund Advisors raised its position in Nabriva Therapeutics AG by 4.6% in the second quarter. Nationwide Fund Advisors now owns 180,924 shares of the biotechnology company’s stock valued at $2,032,000 after buying an additional 7,924 shares in the last quarter. Royal Bank of Canada raised its position in Nabriva Therapeutics AG by 19.6% in the second quarter. Royal Bank of Canada now owns 52,807 shares of the biotechnology company’s stock valued at $553,000 after buying an additional 8,650 shares in the last quarter. Renaissance Technologies LLC purchased a new position in Nabriva Therapeutics AG during the fourth quarter valued at about $103,000. Almanack Investment Partners LLC. purchased a new position in Nabriva Therapeutics AG during the first quarter valued at about $1,870,000. Finally, Wellington Management Group LLP raised its position in Nabriva Therapeutics AG by 9.9% in the first quarter. Wellington Management Group LLP now owns 2,154,261 shares of the biotechnology company’s stock valued at $25,830,000 after buying an additional 193,951 shares in the last quarter. 56.65% of the stock is currently owned by institutional investors and hedge funds.

A number of equities research analysts have recently weighed in on NBRV shares. Wedbush reissued an “outperform” rating and issued a $13.00 target price on shares of Nabriva Therapeutics AG in a research note on Monday, May 15th. Zacks Investment Research raised Nabriva Therapeutics AG from a “hold” rating to a “buy” rating and set a $12.00 price target for the company in a research report on Thursday, August 10th. Cantor Fitzgerald started coverage on Nabriva Therapeutics AG in a research report on Thursday, June 22nd. They set a “buy” rating and a $16.00 price target for the company. ValuEngine lowered Nabriva Therapeutics AG from a “hold” rating to a “sell” rating in a research report on Tuesday, August 1st. Finally, HC Wainwright reaffirmed a “buy” rating and set a $16.00 price target on shares of Nabriva Therapeutics AG in a research report on Friday, June 30th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and six have issued a buy rating to the stock. Nabriva Therapeutics AG currently has a consensus rating of “Buy” and an average target price of $15.43.

Nabriva Therapeutics AG Company Profile

Nabriva Therapeutics plc is a clinical stage biopharmaceutical company. The Company is engaged in engaged in the research and development of novel anti-infectives to treat serious infections, with a focus on the pleuromutilin class of antibiotics. The Company’s medicinal chemistry has enabled targeted discovery of novel pleuromutilins, including both intravenous and oral formulations of its lead product candidate, lefamulin.

Insider Buying and Selling by Quarter for Nabriva Therapeutics AG (NASDAQ:NBRV)

Receive News & Stock Ratings for Nabriva Therapeutics AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nabriva Therapeutics AG and related stocks with our FREE daily email newsletter.